31st Jul 2006 09:27
Henderson Morley PLC31 July 2006 FOR IMMEDIATE RELEASE 31 JULY 2006 HENDERSON MORLEY PLC (AIM) Business: Drug Discovery Company HENDERSON MORLEY GRANTS LICENCE TO AMISTAD PHARMA The Board of Henderson Morley plc, ("Henderson Morley" or "the Company") the AIM listed drug discovery company, is pleased to announce that it has granted a licence in respect of Ionic Contra Viral Therapy ("ICVT") to AMISTAD PHARMA, a company whose focus is mainly on women's health care. Key Points: •The Licence has been granted to Amistad Pharma - an independent French pharmaceutical company specialising in women's healthcare; •This will be an exclusive worldwide licence to bring products to market through a programme of pre-clinical and clinical development; •Amistad will pay Henderson Morley 40% of all Net Receipts received in respect of sub-licences; •Henderson Morley will receive a royalty equal to 10% of AMISTAD sales. The Licence has been granted to Amistad Pharma SAS, an independent French pharmaceutical company specialising in women's healthcare. Chairman of Amistad is Dr Alain Munoz. Dr. Alain Munoz was formerly VP of R & D and Business Development for the French pharmaceutical company, Fournier. He isalso a former member of the scientific committee of the French Drug Agency (Agence du Medicament). He has an in-depth knowledge of the US and Japanesemarkets, and has concluded several major licensing deals with world-class partners in the industry. The License Agreement is for a new application of ICVT for the topical treatment of genital and labial herpes and certain other dysplasias. The licence will be an exclusive worldwide licence to bring the products to market through a programme of pre-clinical and clinical development of the treatment either by Amistad or through a sub-licence. Amistad is obliged to conduct and complete certain pre-clinical and pre-development milestones including formulation, at its cost, within a period of 18 months from the date that is 45 days after 27 July 2006. Amistad shall pay Henderson Morley 40% of all Net Receipts received by Amistador its Associates where "Net Receipts" means all royalties, licence fees,development milestone payments and other comparable fees or other valuableconsideration received by Amistad or its Associates from its Sub-Licensees inrespect of the sub-licence of the Henderson Morley Technology. Amistad shall pay to Henderson Morley a royalty 10% of the aggregate Net Salesof all Licensed Products sold by or for the account of Amistad or itsAssociates. Amistad will be expected to: •develop at least one commercially viable Licensed Product; •obtain or cause to be obtained Product Approvals for at least one Licensed Product; and •commercially launch at least one Licensed Product in each country where Product Approval has been granted Commenting on the Agreement, Executive Chairman Andrew Knight said: "We are verypleased to have signed this licence with Amistad. Dr Munoz is a well respectedfigure in the pharmaceutical industry and we look forward to working with himand his team to bring the ICVT products to market." Dr Alain Munoz, Chairman of Amistad also commented: "The ICVT technology willfit very well with the Amistad proprietary technology and I am delighted that,together with Henderson Morley, we will develop an innovative product in an areawhere there is an unsatisfied medical need." --ENDS-- Enquiries: HENDERSON MORLEY PLC Tel: 0121 442 4600Andrew Knight, Chairman BREWIN DOLPHIN SECURITIES LTD Tel: 0113 241 0126Neil Baldwin BISHOPSGATE COMMUNICATIONS LTD Tel: 020 7430 1600Maxine Barnes Mobile: 07860 489571Scott Robertson This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
HML.L